Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06550141 · ClinicalTrials.gov registry record · Phase 2

Emapalumab Prevention of CAR-T Cell Associated Toxicities

A Phase 2 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma, sponsored by Marcela V. Maus, M.D.,Ph.D..

Recruiting
Registry status
Phase 2
Development phase
28
Enrollment target
2
Study locations

NCT06550141 is a Phase 2 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 28 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06550141, a Phase 2 study of Diffuse Large B Cell Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Marcela V. Maus, M.D.,Ph.D..

RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
2
Study locations

Study Summary

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab

Conditions Studied

Diffuse Large B Cell Lymphoma Follicular Lymphoma Large B-cell Lymphoma High Grade B-Cell Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma Primary Mediastinal Large B Cell Lymphoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine Phosphate
  • DRUG Axicabtagene Ciloleucel
  • DRUG Emapalumab

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2024-09-18
Est. Completion 2027-08-01
Phase Phase 2

Sponsor

Marcela V. Maus, M.D.,Ph.D.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06550141

The ClinicalTrials.gov registry entry for NCT06550141 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (87% lower). The listed sponsor is Marcela V. Maus, M.D.,Ph.D., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT06550141 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06550141 about?

NCT06550141 is a clinical study titled "Emapalumab Prevention of CAR-T Cell Associated Toxicities". This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepletin...

What is the current status of trial NCT06550141?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-09-18. Estimated completion is 2027-08-01.

What conditions does trial NCT06550141 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, High Grade B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT06550141?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine Phosphate (DRUG), Axicabtagene Ciloleucel (DRUG), Emapalumab (DRUG).

Who is sponsoring clinical trial NCT06550141?

This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06550141 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Follicular Lymphoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.